Resistance to bortezomib in breast cancer cells that downregulate Bim through FOXA1 O‐GlcNAcylation

Volume: 234, Issue: 10, Pages: 17527 - 17537
Published: Feb 21, 2019
Abstract
Bortezomib (BTZ), a well-established proteasome inhibitor used in the clinical therapy, leads the modulation of several biological alterations and in turn induces apoptosis. Although clinical trials with BTZ have shown promising results for some types of cancers, but not for some others, including those of the breast. The molecular basis of BTZ resistance in breast cancer remains elusive. In the present study, we found that cellular O-GlcNAc...
Paper Details
Title
Resistance to bortezomib in breast cancer cells that downregulate Bim through FOXA1 O‐GlcNAcylation
Published Date
Feb 21, 2019
Volume
234
Issue
10
Pages
17527 - 17537
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.